Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study

PULSE BIOSCIENCES, INC.

77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).
100% acute lesion success with conduction block; total PVI ablation time 11.6±4.5 minutes.
1 primary SAE (cardiac perforation) and 2 AEs (vertigo, creatinine elevation) all resolved.
Company on track to begin IDE study in 2025 for clinical validation.
Data presented at AF Symposium 2025; live case with 3D mapping on Abbott Ensite X System.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.